<DOC>
	<DOCNO>NCT01025570</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , combination two drug , gemcitabine bosutinib , patient resect pancreatic cancer whether combination prevent pancreatic cancer come back .</brief_summary>
	<brief_title>A Study Evaluating Gemcitabine Plus Bosutinib Patients With Resected Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Histologically proven adenocarcinoma pancreas . Complete resection standard pancreaticoduodenectomy ( tumor pancreatic head ) distal pancreatectomy ( tumor pancreatic tail ) . Positive microscopic margin allowable . No measurable disease . ECOG performance status 0 1 . ≥ 18 year age . Ability start adjuvant therapy within 8 week pancreatic cancer surgery ( sooner 3 week ) . CA 199 ≤ 2.5 time upper limit normal . ANC ( absolute neutrophil count ) ≥ 1500/μL Hemoglobin ≥ 9 gm/dL ( may transfuse may receive epoetin alfa maintain level ) Platelet count ≥ 100,000/μL INR ≤ 1.5 ( except subject receive fulldose warfarin ) Total bilirubin ≤ 2.0 mg/dL AST ALT ≤ 2.5 time upper limit normal Serum creatinine ≤ 2.0 Negative pregnancy test woman childbearing potential ( serum urine betaHCG ) . All patient must inform investigational nature study sign give write informed consent accordance institutional federal guideline . Women men reproductive potential must agree use effective contraceptive method treatment 6 month afterwards . At least one paraffin block patient 's pancreatic cancer surgery must available analysis ( necessarily need received start study treatment ) . Any prior systemic investigational therapy pancreatic cancer . Grossly positive surgical margin . Any following postoperative complication : wound dehiscence infection , intraabdominal abscess , pancreatic biliary leak fistula . History major psychiatric disorder chronic medical illness , opinion treat physician , contraindicates use investigational drug protocol might render subject high risk treatment related complication . Serious active ongoing infection , include require parenteral antibiotic . Patients `` currently active '' second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse . Pregnancy ( positive pregnancy test ) lactation . Known central nervous system disease . Inability swallow pills/tolerate oral intake . Inability comply study and/or followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>pancreas</keyword>
	<keyword>pancreatic</keyword>
	<keyword>bosutinib</keyword>
	<keyword>SKI-606</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>gemzar</keyword>
	<keyword>Patients resect pancreatic cancer</keyword>
</DOC>